FI113865B - Menetelmä 2-aryylisubstituoidut-4-hydroksi-1,2,5,10-tetrahydropyridatsino[4,5-b]-kinoliini-1,10-dionijohdannaisten valmistamiseksi, jotka ovat terapeuttisesti käyttökelpoisia aivojen iskeemisten sairauksien hoidossa - Google Patents

Menetelmä 2-aryylisubstituoidut-4-hydroksi-1,2,5,10-tetrahydropyridatsino[4,5-b]-kinoliini-1,10-dionijohdannaisten valmistamiseksi, jotka ovat terapeuttisesti käyttökelpoisia aivojen iskeemisten sairauksien hoidossa

Info

Publication number
FI113865B
FI113865B FI961696A FI961696A FI113865B FI 113865 B FI113865 B FI 113865B FI 961696 A FI961696 A FI 961696A FI 961696 A FI961696 A FI 961696A FI 113865 B FI113865 B FI 113865B
Authority
FI
Finland
Prior art keywords
phenyl
quinoline
deriv
tetrahydropyridazino
aryl
Prior art date
Application number
FI961696A
Other languages
English (en)
Swedish (sv)
Other versions
FI961696A (fi
FI961696A0 (fi
Inventor
Thomas Michael Bare
Richard Bruce Sparks
James Roy Empfield
Timothy Wayne Davenport
Jeffrey Alan Mckinney
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939321854A external-priority patent/GB9321854D0/en
Priority claimed from GB9417171A external-priority patent/GB9417171D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of FI961696A publication Critical patent/FI961696A/fi
Publication of FI961696A0 publication Critical patent/FI961696A0/fi
Priority to FI970907A priority Critical patent/FI114916B/fi
Application granted granted Critical
Publication of FI113865B publication Critical patent/FI113865B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
FI961696A 1993-10-22 1996-04-18 Menetelmä 2-aryylisubstituoidut-4-hydroksi-1,2,5,10-tetrahydropyridatsino[4,5-b]-kinoliini-1,10-dionijohdannaisten valmistamiseksi, jotka ovat terapeuttisesti käyttökelpoisia aivojen iskeemisten sairauksien hoidossa FI113865B (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI970907A FI114916B (fi) 1993-10-22 1997-03-03 Menetelmä 2-aryylisubstituoidut-4-hydroksi-1,2,5,10-tetrahydropyridatsino- [4,5-b]kinoliini-1,10-dionijohdannaisten valmistamiseksi, jotka ovat terapeuttisesti käyttökelpoisia aivojen iskeemisten sairauksien hoidossa

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939321854A GB9321854D0 (en) 1993-10-22 1993-10-22 Pyridazino quinoline compounds
GB9417171A GB9417171D0 (en) 1994-08-25 1994-08-25 Pyridazino quinoline compounds
PCT/GB1994/002295 WO1995011244A1 (en) 1993-10-22 1994-10-20 Pyridazino quinoline compounds

Publications (3)

Publication Number Publication Date
FI961696A FI961696A (fi) 1996-04-18
FI961696A0 FI961696A0 (fi) 1996-04-18
FI113865B true FI113865B (fi) 2004-06-30

Family

ID=26303731

Family Applications (2)

Application Number Title Priority Date Filing Date
FI961696A FI113865B (fi) 1993-10-22 1996-04-18 Menetelmä 2-aryylisubstituoidut-4-hydroksi-1,2,5,10-tetrahydropyridatsino[4,5-b]-kinoliini-1,10-dionijohdannaisten valmistamiseksi, jotka ovat terapeuttisesti käyttökelpoisia aivojen iskeemisten sairauksien hoidossa
FI970907A FI114916B (fi) 1993-10-22 1997-03-03 Menetelmä 2-aryylisubstituoidut-4-hydroksi-1,2,5,10-tetrahydropyridatsino- [4,5-b]kinoliini-1,10-dionijohdannaisten valmistamiseksi, jotka ovat terapeuttisesti käyttökelpoisia aivojen iskeemisten sairauksien hoidossa

Family Applications After (1)

Application Number Title Priority Date Filing Date
FI970907A FI114916B (fi) 1993-10-22 1997-03-03 Menetelmä 2-aryylisubstituoidut-4-hydroksi-1,2,5,10-tetrahydropyridatsino- [4,5-b]kinoliini-1,10-dionijohdannaisten valmistamiseksi, jotka ovat terapeuttisesti käyttökelpoisia aivojen iskeemisten sairauksien hoidossa

Country Status (30)

Country Link
US (3) US5744471A (fi)
EP (2) EP0724583B1 (fi)
JP (1) JP3583132B2 (fi)
KR (1) KR100261209B1 (fi)
CN (1) CN1053189C (fi)
AT (2) ATE198072T1 (fi)
AU (2) AU688393B2 (fi)
CA (1) CA2171332A1 (fi)
CZ (1) CZ292311B6 (fi)
DE (2) DE69426422T2 (fi)
DK (2) DK1004582T3 (fi)
ES (2) ES2241513T3 (fi)
FI (2) FI113865B (fi)
GB (1) GB9420590D0 (fi)
GR (1) GR3035080T3 (fi)
HK (1) HK1013997A1 (fi)
HU (1) HUT74161A (fi)
IL (1) IL111266A (fi)
MY (2) MY132875A (fi)
NO (1) NO306995B1 (fi)
NZ (2) NZ329303A (fi)
PL (1) PL180679B1 (fi)
PT (2) PT724583E (fi)
RU (1) RU2168511C2 (fi)
SG (2) SG59971A1 (fi)
SI (2) SI0724583T1 (fi)
SK (1) SK282491B6 (fi)
TW (1) TW406082B (fi)
UA (1) UA60291C2 (fi)
WO (1) WO1995011244A1 (fi)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9420590D0 (en) * 1993-10-22 1994-11-30 Zeneca Ltd Pyridazino quinoline compounds
US6214826B1 (en) 1994-11-12 2001-04-10 Zeneca Limited Pyridazino quinoline compounds
GB9422894D0 (en) * 1994-11-12 1995-01-04 Zeneca Ltd Pyridazino quinoline compounds
GB9507318D0 (en) * 1995-04-07 1995-05-31 Zeneca Ltd Alpha substituted pyridazino quinoline compounds
JP2003519146A (ja) * 1999-12-23 2003-06-17 アストラゼネカ・アクチエボラーグ 痛みの処置のための方法および組成物
AU2566201A (en) * 1999-12-23 2001-07-09 Astrazeneca Ab Compounds and methods for the treatment of pain
US20050124622A1 (en) * 1999-12-23 2005-06-09 Brown Dean G. Compounds and methods for the treatment of pain
EP1244453A1 (en) * 1999-12-23 2002-10-02 AstraZeneca AB Method and composition for the treatment of pain
US6943165B2 (en) * 1999-12-23 2005-09-13 Astrazeneca Ab Compound and method for the treatment of pain
US20030176435A1 (en) * 2002-12-17 2003-09-18 Brown Dean Gordon Compounds and methods for the treatment of pain
US6787547B2 (en) 1999-12-23 2004-09-07 Astrazeneca Ab Compound and method for the treatment of pain
US6730675B2 (en) 1999-12-23 2004-05-04 Astrazeneca Ab Compounds and methods for the treatment of pain
EP1248621A1 (en) * 1999-12-23 2002-10-16 AstraZeneca AB Method and composition for the treatment of pain
SI1244662T1 (fi) * 1999-12-23 2005-08-31 Astrazeneca Ab
DE60013326T2 (de) * 1999-12-23 2005-09-08 Astrazeneca Ab Verbindungen und verfahren zur behandlung von schmerz
BR0016654A (pt) * 1999-12-23 2002-09-03 Astrazeneca Ab Composto, método para o tratamento da dor, e, composição farmacêutica
US6403818B1 (en) 2000-02-28 2002-06-11 Eisai Co., Ltd. Process for producing α-hydroxy-carbonyl compound
WO2002026739A1 (en) * 2000-09-29 2002-04-04 Astrazeneca Ab 1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-diones and their use for the treatment of pain
WO2002026741A1 (en) * 2000-09-29 2002-04-04 Astrazeneca Ab 1,2,5,10-TETRAHYDROPYRIDAZINO[4,5-b]QUINOLINE-1,10-DIONES AND THEIR USE FOR THE TREATMENT OF PAIN
EP1325002B1 (en) 2000-09-29 2006-05-24 AstraZeneca AB 1,2,5,10-tetrahydropyridazino¬4,5-b|quinoline-1,10-diones and their use for the treatment of pain
DE60121978D1 (de) * 2000-09-29 2006-09-14 Astrazeneca Ab 7-CHLOR-4-HYDROXY-2-(2-PYRIDYLETHYL)-1,2,5,10-TETRAHYDROPYRIDAZINOi4,5-BöCHINOLIN-1,10-DIONE UND IHRE VERWENDUNG ZUR BEHANDLUNG VON SCHMERZEN
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
WO2002096879A1 (en) 2001-05-31 2002-12-05 Sanofi-Synthelabo Aminoquinoline and aminopyridine derivatives and their use as adenosine a3 ligands
US8592421B2 (en) 2003-08-04 2013-11-26 Valery Khazhmuratovich Zhilov Cyclic bioisosters of purine system derivatives and a pharmaceutical composition based thereon
HUE032540T2 (en) 2004-06-24 2017-09-28 Vertex Pharma Modulators of ATP-binding cassette transporters
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
CA2634113A1 (en) * 2005-12-24 2007-07-05 Vertex Pharmaceuticals Incorporated Quinolin- 4 - one derivatives as modulators of abc transporters
PL1993360T3 (pl) * 2005-12-28 2017-08-31 Vertex Pharmaceuticals Incorporated Stałe postacie n-[2,4-bis(1,1-dimetyloetylo)-5-hydroksyfenylo]-1,4- dihydro-4-oksochinolino-3-karboksyamidu
WO2010108162A1 (en) 2009-03-20 2010-09-23 Vertex Pharmaceuticals Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
US20130224293A1 (en) 2012-02-27 2013-08-29 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
JP6746569B2 (ja) 2014-10-07 2020-08-26 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9109972D0 (en) * 1991-05-09 1991-07-03 Ici Plc Therapeutic compounds
GB9208511D0 (en) * 1991-05-09 1992-06-03 Ici Plc Compounds
GB9420590D0 (en) * 1993-10-22 1994-11-30 Zeneca Ltd Pyridazino quinoline compounds
GB9422894D0 (en) * 1994-11-12 1995-01-04 Zeneca Ltd Pyridazino quinoline compounds
GB9507318D0 (en) * 1995-04-07 1995-05-31 Zeneca Ltd Alpha substituted pyridazino quinoline compounds

Also Published As

Publication number Publication date
NO961584D0 (no) 1996-04-19
DK1004582T3 (da) 2005-08-15
HU9600889D0 (en) 1996-06-28
DE69434380D1 (de) 2005-06-23
FI970907A (fi) 1997-03-03
AU721139B2 (en) 2000-06-22
FI970907A0 (fi) 1997-03-03
NO306995B1 (no) 2000-01-24
CN1138332A (zh) 1996-12-18
PL314041A1 (en) 1996-08-05
ATE295846T1 (de) 2005-06-15
CZ292311B6 (cs) 2003-09-17
EP1004582B1 (en) 2005-05-18
SG59971A1 (en) 1999-02-22
DE69426422D1 (de) 2001-01-18
EP0724583B1 (en) 2000-12-13
EP1004582A2 (en) 2000-05-31
RU2168511C2 (ru) 2001-06-10
EP1004582A3 (en) 2000-08-30
SK282491B6 (sk) 2002-02-05
CA2171332A1 (en) 1995-04-27
WO1995011244A1 (en) 1995-04-27
NO961584L (no) 1996-04-19
FI114916B (fi) 2005-01-31
ES2154686T3 (es) 2001-04-16
MY124316A (en) 2006-06-30
ATE198072T1 (de) 2000-12-15
SK50496A3 (en) 1997-03-05
JP3583132B2 (ja) 2004-10-27
GR3035080T3 (en) 2001-03-30
AU7944094A (en) 1995-05-08
CZ113896A3 (en) 1996-09-11
FI961696A (fi) 1996-04-18
KR100261209B1 (ko) 2000-09-01
UA60291C2 (uk) 2003-10-15
NZ329303A (en) 2000-01-28
DE69434380T2 (de) 2006-05-04
AU6899998A (en) 1998-07-30
HK1013997A1 (en) 1999-09-17
IL111266A0 (en) 1994-12-29
AU688393B2 (en) 1998-03-12
EP0724583A1 (en) 1996-08-07
PT1004582E (pt) 2005-09-30
TW406082B (en) 2000-09-21
DE69426422T2 (de) 2001-05-10
US6103721A (en) 2000-08-15
CN1053189C (zh) 2000-06-07
GB9420590D0 (en) 1994-11-30
FI961696A0 (fi) 1996-04-18
HUT74161A (en) 1996-11-28
IL111266A (en) 2002-03-10
ES2241513T3 (es) 2005-11-01
US6232313B1 (en) 2001-05-15
PL180679B1 (en) 2001-03-30
DK0724583T3 (da) 2001-03-05
JPH09504519A (ja) 1997-05-06
NZ275472A (en) 1998-03-25
SI0724583T1 (en) 2001-04-30
US5744471A (en) 1998-04-28
MY132875A (en) 2007-10-31
PT724583E (pt) 2001-03-30
SG92630A1 (en) 2002-11-19
SI1004582T1 (fi) 2005-08-31

Similar Documents

Publication Publication Date Title
FI113865B (fi) Menetelmä 2-aryylisubstituoidut-4-hydroksi-1,2,5,10-tetrahydropyridatsino[4,5-b]-kinoliini-1,10-dionijohdannaisten valmistamiseksi, jotka ovat terapeuttisesti käyttökelpoisia aivojen iskeemisten sairauksien hoidossa
BR9707495A (pt) Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
EA199901014A1 (ru) C-4"-замещенные макролидные производные
TNSN87015A1 (fr) Nouvelles n-heterocyclyl-4-piperidinamines, compositions contenant des n-heterocyclyl-4-piperidinamines, procede de traitement les utilisant et procede pour preparer des n-heterocyclyl-4- piperidinamines
KR920701165A (ko) 골수세포형성 촉진에 유용한 헤테로아릴-3-옥소-프로판니트릴 유도체
DE60216610D1 (de) Verwendung von kondensierten Pyrazolverbindungen für die Herstellung eines Arzneimittels zur Behandlung von Bluthochdruck
SE9904177D0 (sv) Novel compounds
ATE404558T1 (de) Antimikrobielle 4-oxochinolizinverbindungen, die als teilstruktur ein 2-pyridonskelett aufweisen
ZA928684B (en) Benzimidazole anthelmintic agents